818-P: Effects of Insulin Efsitora Alfa (Efsitora) on Frequency and Severity of Hypoglycemia (Hypo) Under Conditions of Increased Hypo Risk Compared with Glargine in Type 2 Diabetes (T2D)

Introduction 70 mg/dL) was not significantly different under any test condition: incidence efsitora vs glargine, difference in proportion (95%CI) for PF: 44.7 vs 42.6%, 2.1 (-17.2, 21.4); EX: 65.9 vs 50.0%, 15.9 (-3.0, 34.8); DD: 68.1 vs 61.7%, 6.4 (-12.8, 25.6). Level 1 hypo resolved spontaneously or after 15g oral glucose. Level 2 (54 mg/dL) was infrequent in both treatments and all test conditions. No severe hypo occurred in this study. Mean nadir glucose for hypo was similar between treatments and test conditions ranging from 62.8-66.3 mg/dL. Duration of hypo events was also similar between treatments ranging from 76.6 to 115.2 mins depending on the test condition. Conclusion: Once weekly efsitora did not increase the incidence, duration, or severity of hypo compared to once daily glargine during periods of provocation in patients with T2D. Disclosure T. Heise: Research Support; ADOCIA, AstraZeneca, Biocon, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Genova, Novo Nordisk A/S. Consultant; Gan Eli Lilly and Company. Research Support; Altimmune Inc., Sanofi, Zealand Pharma A/S, BIOTON, Civica Foundation, Enyo Pharma, Gan Profil Institut für Stoffwechselforschung GmbH. E.J. Pratt: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. J. Leohr: None. T. Fukuda: Employee; Eli Lilly and Company. Q. Wang: Employee; Eli Lilly and Company. C.M. Kazda: Employee; Eli Lilly and Company. J.M. Bue-Valleskey: Employee; Eli Lilly and Company. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S. Funding This research was funded by Eli Lilly and Company.